---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-010634"
form_type: "8-K"
ticker: "PMHS"
cik: "0001265521"
company_name: "Polomar Health Services, Inc."
filed_at: "2025-03-17T23:59:59+00:00"
generated_at: "2026-05-24T15:15:33.451449+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Polomar Health signs exclusive distribution deal for inhalable sildenafil and sumatriptan

## Summary
- Agreement with ForHumanity Health and Island 40 Group grants exclusivity through Sep 30, 2025, in exchange for $750,000 guaranteed revenue.
- ForHumanity made a $250,000 advance payment to secure exclusivity; remaining $500,000 due by June 30, 2025.
- Initial term of 3 years through March 2028; auto-renewal for up to 5-year terms if revenue targets met (minimum $3M average annually for first renewal).
- Exclusivity can be extended through Dec 31, 2028, if ForHumanity achieves escalating revenue milestones (e.g., $20M by 2027).
- Polomar Specialty Pharmacy will fulfill prescriptions; IG4 handles account management.

## SEC filing metadata
- accession: 0001493152-25-010634
- form_type: 8-K
- ticker: PMHS
- cik: 0001265521
- company_name: Polomar Health Services, Inc.
- filed_at: 2025-03-17T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1265521/000149315225010634/0001493152-25-010634-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1265521/000149315225010634/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-010634
- JSON: https://secwatch.observer/filing/0001493152-25-010634.json
- Plain text: https://secwatch.observer/filing/0001493152-25-010634.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.